RNA Therapeutics Market - By Product (Vaccines, Drugs), Type (mRNA Therapeutics, RNA Interference Therapeutics, siRNA Therapeutics), Indication (Infectious Diseases, Autoimmune Disorders), End-use (Hospitals, Research Institutes), Global Forecast, 2024 – 2032

RNA Therapeutics Market Size

RNA Therapeutics Market size was valued at USD 19.2 billion in 2023 and is estimated to grow at a CAGR of 5.7% from 2024 to 2032. The rising incidence of infectious diseases has propelled the demand for innovative and targeted treatment options, with RNA therapeutics emerging as a promising solution.
 

Similarly, increasing incidence of rare diseases and genetic disorders has fuelled the demand for personalized medicine, where RNA therapies play a pivotal role. For instance, as per WHO, genetic disorders and congenital abnormalities occur in about 2%-5% of all live births and account for up to 30% of paediatric hospital admissions in industrialized countries. This high incidence of genetic disorders contributes to an increased demand for new therapeutic interventions, thereby fostering the market expansion.
 

Additionally, the success of RNA-based COVID-19 vaccines has highlighted the potential of RNA therapeutics, garnering significant attention and investment. Thus, as the field continues to mature, the RNA therapeutics market is poised for continued growth.
 

RNA therapeutics refers to a class of medical interventions that utilize ribonucleic acid (RNA) molecules to treat or prevent diseases. RNA, a molecule involved in the expression of genetic information, plays a crucial role in the synthesis of proteins in cells. RNA therapeutics hold promise for treating a wide range of diseases, including genetic disorders, cancer, infectious diseases, and various other conditions.
 

RNA Therapeutics Market Trends

• The RNA therapeutic market has experienced a significant boost in recent years, largely attributed to the increasing trend of partnerships and collaborations among market players.
   
• As pharmaceutical and biotechnology companies recognize the potential of RNA-based therapies in addressing various diseases, they are actively engaging in strategic alliances to pool resources, share expertise, and expedite the development and commercialization of RNA therapeutics.
   
• For instance, in February 2023, Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines and Life Edit Therapeutics Inc., signed a strategic R&D collaboration to discover and develop in vivo mRNA gene editing therapies.
   
• Such growing collaborations among market players in the RNA therapeutic sector are pivotal in accelerating innovation and advancing the development of transformative treatments, thereby fostering the robust growth of market.
   

However, the intricate nature of RNA-based drugs, including the need for advanced technologies and specialized expertise, contributes to elevated development costs. Additionally, manufacturing RNA therapeutics involves sophisticated processes and quality control measures, further increasing production expenses.
 

RNA Therapeutics Market Analysis

Based on product, the RNA therapeutic market is segmented into vaccines and drugs. The vaccines segment held largest business share of 71.7% in 2023.
 

• High market share can be attributed to the ability of RNA vaccines to induce robust and specific immune responses. Also, the success of RNA vaccines in combating infectious diseases, especially COVID-19 virus, has further propelled the market share of this segment.
   
• Further, with ongoing advancements in RNA therapeutic research and the increasing recognition of their potential in preventing a wide array of diseases, the vaccines segment is poised to maintain its dominance, contributing significantly to the market progress.

Based on type, the RNA therapeutics market is classified into mRNA therapeutics, RNA interference (RNAi) therapeutics, antisense oligonucleotide (ASO) therapeutics, siRNA (small interfering RNA) therapeutics, and other types. The mRNA therapeutics segment was valued at USD 12.6 billion in 2023.
 

• mRNA-based therapies exhibit a remarkable versatility, as they can be designed and tailored to address a diverse range of medical conditions, including infectious diseases, cancers, and genetic disorders.
   
• Availability of several mRNA vaccines in pipeline and clinical trials for wide applications will further enhances its segmental growth. Moreover, the approval of COVID-19 mRNA vaccines such as the Pfizer-BioNTech and Moderna significantly increased the confidence in the efficacy and safety of mRNA technology, further boosting the segmental growth.
   

Based on indications, the RNA therapeutics market is segmented into infectious diseases, hereditary/genetic diseases, autoimmune disorders, and other indications. The infectious diseases segment is anticipated to grow at a CAGR of 5.5% between 2024 and 2032 to reach USD 19.4 billion by 2032.
 

• Rising global burden of infectious diseases, coupled with the emergence of new and drug-resistant pathogens, has increased the adoption of advanced therapeutic interventions including RNA therapeutics for the treatment.
   
• Also, rapid advancements in RNA-based technologies, including messenger RNA (mRNA) vaccines and siRNA therapies is expected to contribute significantly to the segment landscape.
   

Based on end-use, the RNA therapeutics market is segmented into hospitals, academic & research institutes, and other end-users. The hospital segment is further divided into public and private.
 

• Hospital segment dominated the market in 2023 and is anticipated to witness similar trend over the forecast years.
   
• Hospitals are increasingly recognizing the therapeutic potential of RNA-based treatments for a wide range of diseases. Hence, the setting become an epicenter for drugs or vaccine availability, thus supplementing the market growth.
   
• Further, these healthcare settings benefit from established infrastructure along with the presence of trained healthcare professionals, collaboration with public health campaigns, and insurance coverage.

In 2023, North America held a significant share of 36% in the global RNA therapeutics market.
 

• High regional share can be attributed to factors such as robust research and development initiatives, strategic collaborations between pharmaceutical companies and research institutions, and a favorable regulatory environment that supports the advancement of RNA-based therapeutics.
   
• Further, the presence of leading pharmaceutical and biotechnology companies, along with academic institutions engaged in advanced biomedical research, contributes significantly to the region's dominance.
   
• Additionally, the region's strong healthcare system and high levels of investment in healthcare technology also play a pivotal role in the widespread adoption of RNA therapeutics, thereby solidifying the region's foothold in this market.
   

RNA Therapeutics Market Share

The global RNA therapeutics industry is characterized by the active participation of key pharmaceutical companies and biotech firms. Leading players such as Moderna Inc., Novartis AG, and Pfizer Inc. have established themselves as major contributors to the market. These players are constantly engaging in strategic initiatives such as collaborations, partnerships, and R&D activities to again competitive advantage in the market.
 

RNA Therapeutics Market Companies

Foremost players operating in the RNA therapeutics industry are as mentioned below:

• Alnylam Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals, Inc.
• BioNTech SE
• Ionis Pharmaceuticals
• Moderna Inc.
• Novartis AG
• Orna Therapeutics, Inc.
• Pfizer Inc.
• Sanofi
• Sarepta Therapeutics, Inc.
   

RNA Therapeutics Industry News:

• In September 2023, Moderna Inc. received authorization from Health Canada for its COVID-19 booster vaccine, mRNA-1273.214 (Spikevax Bivalent Original/Omicron). This approval is expected to help the company commercialize its product in Canada, thereby increasing its sales.
   
• In September 2022, Alnylam Pharmaceuticals, Inc. received marketing authorization from the European Commission (EC) for its RNAi therapeutic agent - AMVUTTRA (vutrisiran). The therapy is indicated for treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients. With this approval the company was able to outreach to untapped economies in the Europe region.
   

The RNA therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Vaccines
• Drugs

Market, By Type

• mRNA therapeutics
• Antisense oligonucleotide (ASO) therapeutics
• siRNA (small interfering RNA) therapeutics
• RNA interference (RNAi) therapeutics
• Other types

Market, By Indication

• Infectious diseases
• Hereditary/genetic diseases
• Autoimmune disorders
• Other indications

Market, By End-use

• Hospitals
  • Private
  • Public 
• Academic & research institutes
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa